Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.
One dose of AstraZeneca’s monoclonal antibody cocktail protects against COVID-19 for six months or longer.
Molecular Partners and Novartis believe in the success of DARPins.
Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.
A monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology successfully counteracts a new strain of SARS-CoV-2.